← Back to headlines
mRNA Melanoma Vaccine Shows Sustained Benefits, Cuts Recurrence Risk by Nearly 50%
A new mRNA melanoma vaccine developed by Merck and Moderna has demonstrated sustained benefits over five years, significantly reducing the risk of cancer recurrence or death by almost half in trials.
2 Jun, 17:03 — 2 Jun, 17:03
